Susheel Kodali1, Vinod H Thourani2, Jonathon White3, S Chris Malaisrie4, Scott Lim5, Kevin L Greason6, Mathew Williams7, Mayra Guerrero8, Andrew C Eisenhauer9, Samir Kapadia10, Dean J Kereiakes11, Howard C Herrmann12, Vasilis Babaliaros2, Wilson Y Szeto12, Rebecca T Hahn3, Philippe Pibarot13, Neil J Weissman14, Jonathon Leipsic15, Philipp Blanke15, Brian K Whisenant16, Rakesh M Suri10, Raj R Makkar17, Girma M Ayele18, Lars G Svensson10, John G Webb15, Michael J Mack19, Craig R Smith3, Martin B Leon3. 1. Columbia University Medical Center, New York-Presbyterian Hospital, 177 Fort Washington Avenue, Room 501, New York, NY 10032, USA skodali@columbia.edu. 2. Emory University School of Medicine, Atlanta, GA, USA. 3. Columbia University Medical Center, New York-Presbyterian Hospital, 177 Fort Washington Avenue, Room 501, New York, NY 10032, USA. 4. Northwestern University, Chicago, IL, USA. 5. University of Virginia, Charlottesville, VA, USA. 6. Mayo Clinic, Rochester, MN, USA. 7. NYU Langone Medical Center, New York, NY, USA. 8. NorthShore University HealthSystem, Evanston, IL, USA. 9. Central Maine Heart and Vascular Institute, Lewiston, ME, USA Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. 10. Cleveland Clinic, Cleveland, OH, USA. 11. The Christ Hospital, Cincinnati, OH, USA. 12. University of Pennsylvania, Philadelphia, PA, USA. 13. Laval University, Quebec, QC, Canada. 14. Medstar Health Research Institute and Georgetown University, Washington, DC, USA. 15. St Paul's Hospital, Vancouver, BC, Canada. 16. Intermountain Medical Center, Salt Lake City, UT, USA. 17. Cedars-Sinai Medical Center, Los Angeles, CA, USA. 18. Cardiovascular Research Foundation, New York, NY, USA. 19. Baylor Scott and White Healthcare, Plano, TX, USA.
Abstract
AIMS: Based on randomized trials using first-generation devices, transcatheter aortic valve replacement (TAVR) is well established in the treatment of high-risk (HR) patients with severe aortic stenosis (AS). To date, there is a paucity of adjudicated, prospective data evaluating outcomes with newer generation devices and in lower risk patients. We report early outcomes of a large, multicentre registry of inoperable, HR, and intermediate-risk (IR) patients undergoing treatment with the next-generation SAPIEN 3 transcatheter heart valve (THV). METHODS AND RESULTS: Patients with severe, symptomatic AS (583 high surgical risk or inoperable and 1078 IR) were enrolled in a multicentre, non-randomized registry at 57 sites in the USA and Canada. All patients received TAVR with the SAPIEN 3 system via transfemoral (n = 1443, 86.9%) and transapical or transaortic (n = 218, 13.1%) access routes. The rate of 30-day all-cause mortality was 2.2% in HR/inoperable patients [mean Society of Thoracic Surgeons (STS) score 8.7%] and 1.1% in IR patients (mean STS score 5.3%); cardiovascular mortality was 1.4 and 0.9%, respectively. In HR/inoperable patients, the 30-day rate of major/disabling stroke was 0.9%, major bleeding 14.0%, major vascular complications 5.1%, and requirement for permanent pacemaker 13.3%. In IR patients, the 30-day rate of major/disabling stroke was 1.0%, major bleeding 10.6%, major vascular complications 6.1%, and requirement for permanent pacemaker 10.1%. Mean overall Kansas City Cardiomyopathy Questionnaire score increased from 47.8 to 67.8 (HR/inoperable, P < 0.0001) and 54.7 to 74.0 (IR, P < 0.0001). Overall, paravalvular regurgitation at 30 days was none/trace in 55.9% of patients, mild in 40.7%, moderate in 3.4%, and severe in 0.0%. Mean gradients among patients with paired baseline and 30-day or discharge echocardiograms decreased from 45.8 mmHg at baseline to 11.4 mmHg at 30 days, while aortic valve area increased from 0.69 to 1.67 cm(2). CONCLUSIONS: The SAPIEN 3 THV system was associated with low rates of 30-day mortality and major/disabling stroke as well as low rates of moderate or severe paravalvular regurgitation. TRIAL REGISTRATION: ClinicalTrials.gov #NCT01314313. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Based on randomized trials using first-generation devices, transcatheter aortic valve replacement (TAVR) is well established in the treatment of high-risk (HR) patients with severe aortic stenosis (AS). To date, there is a paucity of adjudicated, prospective data evaluating outcomes with newer generation devices and in lower risk patients. We report early outcomes of a large, multicentre registry of inoperable, HR, and intermediate-risk (IR) patients undergoing treatment with the next-generation SAPIEN 3 transcatheter heart valve (THV). METHODS AND RESULTS:Patients with severe, symptomatic AS (583 high surgical risk or inoperable and 1078 IR) were enrolled in a multicentre, non-randomized registry at 57 sites in the USA and Canada. All patients received TAVR with the SAPIEN 3 system via transfemoral (n = 1443, 86.9%) and transapical or transaortic (n = 218, 13.1%) access routes. The rate of 30-day all-cause mortality was 2.2% in HR/inoperable patients [mean Society of Thoracic Surgeons (STS) score 8.7%] and 1.1% in IR patients (mean STS score 5.3%); cardiovascular mortality was 1.4 and 0.9%, respectively. In HR/inoperable patients, the 30-day rate of major/disabling stroke was 0.9%, major bleeding 14.0%, major vascular complications 5.1%, and requirement for permanent pacemaker 13.3%. In IR patients, the 30-day rate of major/disabling stroke was 1.0%, major bleeding 10.6%, major vascular complications 6.1%, and requirement for permanent pacemaker 10.1%. Mean overall Kansas City Cardiomyopathy Questionnaire score increased from 47.8 to 67.8 (HR/inoperable, P < 0.0001) and 54.7 to 74.0 (IR, P < 0.0001). Overall, paravalvular regurgitation at 30 days was none/trace in 55.9% of patients, mild in 40.7%, moderate in 3.4%, and severe in 0.0%. Mean gradients among patients with paired baseline and 30-day or discharge echocardiograms decreased from 45.8 mmHg at baseline to 11.4 mmHg at 30 days, while aortic valve area increased from 0.69 to 1.67 cm(2). CONCLUSIONS: The SAPIEN 3 THV system was associated with low rates of 30-day mortality and major/disabling stroke as well as low rates of moderate or severe paravalvular regurgitation. TRIAL REGISTRATION: ClinicalTrials.gov #NCT01314313. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Martin B Leon; Craig R Smith; Michael Mack; D Craig Miller; Jeffrey W Moses; Lars G Svensson; E Murat Tuzcu; John G Webb; Gregory P Fontana; Raj R Makkar; David L Brown; Peter C Block; Robert A Guyton; Augusto D Pichard; Joseph E Bavaria; Howard C Herrmann; Pamela S Douglas; John L Petersen; Jodi J Akin; William N Anderson; Duolao Wang; Stuart Pocock Journal: N Engl J Med Date: 2010-09-22 Impact factor: 91.245
Authors: Rebecca T Hahn; Philippe Pibarot; John Webb; Josep Rodes-Cabau; Howard C Herrmann; Mathew Williams; Raj Makkar; Wilson Y Szeto; Michael L Main; Vinod H Thourani; E Murat Tuzcu; Samir Kapadia; Jodi Akin; Thomas McAndrew; Ke Xu; Martin B Leon; Susheel K Kodali Journal: JACC Cardiovasc Interv Date: 2014-07 Impact factor: 11.195
Authors: Hans Gustav Hørsted Thyregod; Daniel Andreas Steinbrüchel; Nikolaj Ihlemann; Henrik Nissen; Bo Juel Kjeldsen; Petur Petursson; Yanping Chang; Olaf Walter Franzen; Thomas Engstrøm; Peter Clemmensen; Peter Bo Hansen; Lars Willy Andersen; Peter Skov Olsen; Lars Søndergaard Journal: J Am Coll Cardiol Date: 2015-03-15 Impact factor: 24.094
Authors: Vinod H Thourani; Rakesh M Suri; Rebecca L Gunter; Shubin Sheng; Sean M O'Brien; Gorav Ailawadi; Wilson Y Szeto; Todd M Dewey; Robert A Guyton; Joseph E Bavaria; Vasilis Babaliaros; James S Gammie; Lars Svensson; Mathew Williams; Vinay Badhwar; Michael J Mack Journal: Ann Thorac Surg Date: 2014-11-14 Impact factor: 4.330
Authors: Jeffrey J Popma; David H Adams; Michael J Reardon; Steven J Yakubov; Neal S Kleiman; David Heimansohn; James Hermiller; G Chad Hughes; J Kevin Harrison; Joseph Coselli; Jose Diez; Ali Kafi; Theodore Schreiber; Thomas G Gleason; John Conte; Maurice Buchbinder; G Michael Deeb; Blasé Carabello; Patrick W Serruys; Sharla Chenoweth; Jae K Oh Journal: J Am Coll Cardiol Date: 2014-03-19 Impact factor: 24.094
Authors: Ronald K Binder; John G Webb; Alexander B Willson; Marina Urena; Nicolaj C Hansson; Bjarne L Norgaard; Philippe Pibarot; Marco Barbanti; Eric Larose; Melanie Freeman; Eric Dumont; Chris Thompson; Miriam Wheeler; Robert R Moss; Tae-hyun Yang; Sergio Pasian; Cameron J Hague; Giang Nguyen; Rekha Raju; Stefan Toggweiler; James K Min; David A Wood; Josep Rodés-Cabau; Jonathon Leipsic Journal: J Am Coll Cardiol Date: 2013-05-15 Impact factor: 24.094
Authors: Ian T Meredith; Stephen G Worthley; Robert J Whitbourn; Paul Antonis; Joseph K Montarello; Andrew E Newcomb; Siohban Lockwood; Nicole Haratani; Dominic J Allocco; Keith D Dawkins Journal: EuroIntervention Date: 2014-03-20 Impact factor: 6.534
Authors: Thierry Lefèvre; Antonio Colombo; Didier Tchétché; Azeem Latib; Silvio Klugmann; Jean Fajadet; Federico De Marco; Francesco Maisano; Giuseppe Bruschi; Klaudija Bijuklic; Stefano Nava; Neil Weissman; Reginald Low; Martyn Thomas; Christopher Young; Simon Redwood; Michael Mullen; John Yap; Eberhard Grube; Georg Nickenig; Jan-Malte Sinning; Karl Eugen Hauptmann; Ivar Friedrich; Michael Lauterbach; Michael Schmoeckel; Charles Davidson; Joachim Schofer Journal: JACC Cardiovasc Interv Date: 2016-01-11 Impact factor: 11.195
Authors: Michael J Mack; J Matthew Brennan; Ralph Brindis; John Carroll; Fred Edwards; Fred Grover; David Shahian; E Murat Tuzcu; Eric D Peterson; John S Rumsfeld; Kathleen Hewitt; Cynthia Shewan; Joan Michaels; Barb Christensen; Alexander Christian; Sean O'Brien; David Holmes Journal: JAMA Date: 2013-11-20 Impact factor: 56.272
Authors: Adam B Greenbaum; Vasilis C Babaliaros; Marcus Y Chen; Annette M Stine; Toby Rogers; William W O'Neill; Gaetano Paone; Vinod H Thourani; Kamran I Muhammad; Robert A Leonardi; Stephen Ramee; James F Troendle; Robert J Lederman Journal: J Am Coll Cardiol Date: 2016-10-29 Impact factor: 24.094
Authors: Masahiko Asami; Thomas Pilgrim; Stefan Stortecky; Dik Heg; Eva Roost; Stephan Windecker; Lukas Hunziker Journal: Clin Res Cardiol Date: 2019-03-30 Impact factor: 5.460